{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:40:34Z","timestamp":1791229234664,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Although total duration of tyrosine kinase inhibitor (TKI) therapy and of molecular response at 4 log reduction or deeper (MR4) correlates with treatment\u2010free remission (TFR) success after TKI discontinuation, the optimal cut\u2010off values of the duration remain unresolved. Thus, 131 patients were enrolled into the Canadian TKI discontinuation study. The molecular relapse\u2010free survival (mRFS) was defined from imatinib discontinuation till molecular recurrence, that is, major molecular response (MMR) loss and\/or MR4 loss. We evaluated mRFS at 12\u00a0months after imatinib discontinuation, analyzed it according to the imatinib treatment duration and MR4 duration, and calculated <jats:italic>P<\/jats:italic> value, positive (PPV) and negative predictive value (NPV) in the yearly cut\u2010off period of time. The shortest cut\u2010off was sought that met the joint criteria of a <jats:italic>P<\/jats:italic> value\u00a0\u2264\u00a00\u00b705, PPV\u00a0\u2265\u00a060% and NPV\u00a0\u2265\u00a060%. We propose six years as the shortest imatinib duration cut\u2010off with a <jats:italic>P<\/jats:italic> value 0\u00b701, PPV 68% and NPV 62%: The patients treated with imatinib duration\u00a0\u2265\u00a06\u00a0years showed a superior mRFS rate (61\u00b78%) compared to those with less treatment (36\u00b70%). Also, 4\u00b75\u00a0years MR4 duration as the shortest cut\u2010off with a <jats:italic>P<\/jats:italic> value 0\u00b7003, PPV 63% and NPV 61%: those with MR4 duration\u00a0\u2265\u00a04\u00b75\u00a0years showed a higher mRFS rate (64\u00b72%) than those with a shorter MR4 duration (41\u00b79%).<\/jats:p>","DOI":"10.1111\/bjh.17447","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T07:08:35Z","timestamp":1618902515000},"page":"779-791","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Optimal duration of imatinib treatment\/deep molecular response for treatment\u2010free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial"],"prefix":"10.1111","volume":"193","author":[{"given":"Dennis D. H.","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Cancer Centre University Health Network University of Toronto Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Novitzky\u2010Basso","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Cancer Centre University Health Network University of Toronto Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taehyung S.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Cancer Centre University Health Network University of Toronto Toronto Canada"},{"name":"Department of Computer Science Donnelly Centre University of Toronto Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshetu G.","family":"Atenafu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Princess Margaret Cancer Centre University Health Network Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Forrest","sequence":"additional","affiliation":[{"name":"Leukemia\/BMT Program of British Columbia Division of Hematology Vancouver General Hospital British Columbia Cancer Agency, and University of British Columbia Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Savoie","sequence":"additional","affiliation":[{"name":"University of Calgary Alberta Health Services Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bence\u2010Bruckler","sequence":"additional","affiliation":[{"name":"Medicine University of Ottawa Ottawa Hospital Research Institute Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary\u2010Margaret","family":"Keating","sequence":"additional","affiliation":[{"name":"Queen Elizabeth II Health Sciences Centre and Dalhousie University Halifax Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Busque","sequence":"additional","affiliation":[{"name":"Hematopoiesis and Aging Research Unit University of Montreal H\u00f4pital Maisonneuve\u2010Rosemont Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Delage","sequence":"additional","affiliation":[{"name":"Centre Universitaire d\u2019H\u00e9matologie et d\u2019Oncologie de Qu\u00e9bec CHU de Qu\u00e9bec H\u00f4pital de l\u2019Enfant\u2010J\u00e9sus Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anargyros","family":"Xenocostas","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Hematology London Health Sciences Centre University of Western Ontario London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Liew","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Alberta Edmonton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristjan","family":"Paulson","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba Winnipeg Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Stockley","sequence":"additional","affiliation":[{"name":"Department of Pathology Toronto General Hospital University Health Network University of Toronto Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Laneuville","sequence":"additional","affiliation":[{"name":"Division of Hematology McGill University Health Centre Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Cancer Centre University Health Network University of Toronto Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Kamel\u2010Reid","sequence":"additional","affiliation":[{"name":"Department of Pathology Toronto General Hospital University Health Network University of Toronto Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Leber","sequence":"additional","affiliation":[{"name":"Department of Oncology McMaster University Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2914"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.63"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00196-9"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139899"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-1094"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24120"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742205"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2604-x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0264-0"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30192-X"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2334-x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2011.11.018"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000865"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx219"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694265"},{"key":"e_1_2_7_22_1","first-page":"611","article-title":"NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia","volume":"17","author":"Shah NP","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(84)90041-9"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4289"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780120803"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17447","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.17447","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T08:37:37Z","timestamp":1693298257000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.17447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1111\/bjh.17447"],"URL":"https:\/\/doi.org\/10.1111\/bjh.17447","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"2021-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}